

14th Global Gator Meeting
Symposium Day Agenda | June 7, 2024
Bilbao, Spain

8:00 – 9:00 a.m.	Registration/Welcome/Coffee
9:00 – 9:10 a.m.	Welcome from CTI Host
9:10 – 9:15 a.m.	Welcome from Conference Organizers
9:15 – 9:30 a.m.	Welcome and Update from College of Pharmacy Dean
9:30 – 10:30 a.m.	Model-Informed Drug Development Block 1 <ul style="list-style-type: none">• Nieves Velez de Mendizabal, Gilead Sciences• Benjamin Weber, Novo Nordisk• Matthias Fueth, F. Hoffman-La Roche• Valvanera Vozmediano, CTI Life Sciences• Megan Gibbs, AstraZeneca
10:30 – 11:00 a.m.	Coffee Break
11:00 – 12:15 p.m.	Pharmacogenomics / Real-World Evidence Block <ul style="list-style-type: none">• Larissa Cavallari, UF• Tobias Gerhard, Rutgers University• Serena Guo, UF• Almut Winterstein, UF
12:15 – 12:30 p.m.	Presentation of Global Gator Award
12:30 – 12:45 p.m.	Symposium Group Photo
12:45 – 2:15 p.m.	Lunch
2:15 – 3:15 p.m.	Clinical Research Block <ul style="list-style-type: none">• Carol Motycka, UF• Olaf Rose, Paracelsus Medical University• Ina Richling, Katholische Kliniken im Märkischen Kreis• Midas Mulder, Haaglanden Medical Center
3:15 – 3:45 p.m.	Coffee Break
3:45 – 5:00 p.m.	Model-Informed Drug Development Block II <ul style="list-style-type: none">• Stephan Schaller, esqLABS• Mirjam Trame, Certara• Bernd Meibohm, University of Tennessee• Christopher Long, Hesperos• Andreas Kovar, Sanofi

Model-Informed Drug Development Block I

Nonlinear Pharmacokinetics, Receptor Occupancy, and Soluble Target Engagement as Tools to Assess In Vivo Antibody Bioactivity	Nieves Velez de Mendizabal, Gilead Sciences
Mitigating Biases in Pharma R&D with Model-Informed Drug Development	Benjamin Weber, Novo Nordisk
From Discovery to Market: Individualized Treatment Regimen in Ophthalmology	Matthias Fueth, F. Hoffman-La Roche
Collaboration Showcase: The Importance of Academia-Industry Partnerships	Valvanera Vozmediano, CTI Life Sciences

Pharmacogenomics / Real-World Evidence Block

CYP2D6-guided pain management	Larissa Cavallari, UF
Revisiting Lactic Acidosis Risk in Metformin Treated Patients with Renal Impairment	Tobias Gerhard, Rutgers University
Equity in Access to Obesity Treatment	Serena Guo, UF
Collateral Damage: Unintended Exposure to Teratogenic Medications During Pregnancy	Almut Winterstein, UF

Clinical Research Block

Interprofessional Education Simulations: Building Teamwork Through Situational Learning	Carol Motycka, UF
Drug Shortage: Reasons, Impact on Patients and Practitioners and Amelioration Strategies	Olaf Rose, Paracelsus Medical University
Transition Between Care Settings - Practice Standards for Medication Management at Hospital Discharge in Germany	Ina Richling, Katholische Kliniken im Märkischen Kreis
Medication Safety in Patients with Liver Cirrhosis	Midas Mulder, Haaglanden Medical Center

Model-Informed Drug Development Block II

Integrated QSP-PBPK Modelling for Biologics in Drug Discovery and Development	Stephan Schaller, esqLABS
Integrating PMX and QSP Approaches to Guide Step Up Dosing for a Bispecific Antibody	Mirjam Trame, Certara
Pharmacometric Approaches in Preclinical Drug Development of Novel Anti-Infectives	Bernd Meibohm, University of Tennessee
Pharmacokinetic-Pharmacodynamic Modeling for In Vivo Predictions Utilizing Human-on-a-Chip systems	Christopher Long, Hesperos
Development of an Oral Anti-TNF α Inhibitor - Expect the Unexpected	Andreas Kovar, Sanofi